Eat generous amounts of saturated fats like coconut oil and butter or clarified butter. Beef tallow, lard and duck fat are also good, but only if they come from healthy and well-treated animals. Beef or lamb tallow is a better choice than lamb or duck fat. Olive, avocado and macadamia oil are also good fats to use in salads and to drizzle over food, but not for cooking. For more information, have a look at our beginner’s guide to Paleo and fat.
There will be two Opens in 2019. Our first Open of the year just kicked off on February 21st, and will run will 5 weeks. This if Open will be a similar structure to the one we’re used to. The other Open will be in October. The October Open will help determine the athletes participating in the 2020 games. From then on, the Open will be in October only. As of right now, we have no insight as to what the October Open will look like or when the 2020 Games will take place. 
The Open, introduced in 2011 and so-called because participation is open to anyone,[23] is held over five weeks in February–March; a new workout is released on each Thursday night (Pacific Time) and competitors complete the workout and submit their scores online by Monday evening, with either a video or validation by a CrossFit affiliate. Since 2013, Open workout announcements have been broadcast live, and featured two or more past CrossFit Games athletes competing head-to-head immediately following the workout description. Beginning with the 2019 Games, the top athlete from each country and the top 20 overall Open finishers qualify directly to the Games. The Open is also used for seeding purposes at the Games even if an athlete qualified through the sanctioned events; if an athlete qualifies through a sanctioned event but does not do the Open, they will be seeded at the bottom.
The WHO trial (so named because the international team of principal investigators contained World Health Organization members) tested the potential of clofibrate, a “pre-statin” cholesterol-lowering agent, to reduce heart attack morbidity and mortality. The investigators ultimately concluded that clofibrate "cannot be recommended as a lipid-lowering drug for community-wide primary prevention of ischaemic heart disease.” Nevertheless, clofibrate remained in use until 2002, when it was pulled for increasing cancer rates. In their review of studies such as the WHO trial, Uffe Ravnskov and David Diamond observe, “Despite the largely disappointing findings from 50 years of cholesterol lower[ing] trials, the indictment and conviction of cholesterol as the causal agent in CVD [cardiovascular disease] has stood the test of time. … [Yet] the grand effort to reduce cholesterol as a strategy to improve health has failed.”
×